Research Alliance with Novo Nordisk
Novo Nordisk is the world’s leading diabetes therapeutics company, with 95 years of experience of innovation in diabetes care. The company has a longstanding relationship with the University of Oxford, itself a global leader in metabolism research, and in 2017 the Novo Nordisk Research Centre Oxford (NNRCO) was launched as part of a strategic alliance between the two organisations.
About the Oxford-Novo Nordisk Alliance
The alliance between Novo Nordisk and Oxford aims to establish landmark collaborations for the advancement in research for diabetes and cardiometabolic disease with an aim to work towards innovative medicines that make a difference in patients' lives.
Uniquely, the alliance has seen Novo Nordisk establish a presence onsite at the University of Oxford, with the Novo Nordisk Oxford Research Centre (NNRCO) employing up to 100 researchers between 2017 and 2021. These NNRCO researchers work in new state-of-the-art laboratories in the Innovation Building on Old Road Campus, which officially opened on the 12th September 2018.
Collaborative projects have been jointly developed and co-funded via the Strategic Alliance Committee and NNRCO also participates in the training of the next generation of diabetes research scientists by co-sponsoring students.
NNRCO itself is led by Professor Bill Haynes and is composed of four departments: Computational Biology, Discovery Technologies and Genomics, Genetics, and Discovery Biology and Pharmacology.
Therapeutic areas of interest
- Alzheimer's Disease
- Cardiovascular Disease
- Non-alcoholic steatohepatitis (NASH)
- Rare diseases (rare blood and endocrine disorders)
- Focus on patient solutions-oriented enterprise where drug, device, digital, diagnostics and data are fully integrated